Scrip    Clinica    RAJ    Scrip Clinical Research    AnimalPharm
Email ID
Password
Forgotten your password?
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Pricing & Reimbursement
|
Regulation
|
Healthcare Policy
|
Pharmacovigilance
|
Intellectual Property
|
Policy & Regulation - Pricing & Reimbursement
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK Promote your vacancy here
DIRECTORY Scrip Directory 2009
Germany to end free pricing for patented medicines
12 March 2010
Germany's health ministry is planning to introduce compulsory price negotiations for patented drugs between the pharmaceutical industry and health insurers, it confirmed to Scrip. The measure could eventually put an end to free pricing in Europe's ...
Lithuania's new health minister to tackle corruption and make reforms
12 March 2010
Raimondas Sukys has become Lithuania's new health minister taking over the post from the acting health minister Ingrida Simonyte . Lithuania's president Dalia Grybauskaite has asked him to go ahead with the healthcare reform and fight corruption ...
Europe to give €12 million for influenza antiviral projects
12 March 2010
The European Commission will provide €12 million in funding for two new research projects which will develop novel influenza treatments, including against both (A) H1N1 pandemic influenza and (A) H5N1 avian flu. Speaking at an EU influenza meeting ...
NICE and drug budgets under the microscope as UK election looms
12 March 2010
In the run up to the general election the UK's three main political parties say they will support the life sciences industry. But victory for any party could affect the future of NICE, and the drug's budget. 2009 was a good year for the UK life ...
Around 300 drugs exempt from regular price cut under new Japanese provisions
10 March 2010
Around 300 products will escape a reduction in the next regular revision of reimbursement prices for prescription drugs in Japan on April 1st because they meet certain criteria under complex new rules being adopted on a trial basis this ...
 
Market Insight: Big pharma hit by Greece's fiscal crisis
09 March 2010
Hospitals' failure to pay pharmaceutical companies and newly announced price cuts are just some of the challenges facing the sector in Greece, Elizabeth Sukkar, Scrip's world editor, discovers. ...
Market Insight - Pharma sector in Turkey to shrink 25% under tough conditions
02 March 2010
The pharmaceutical industry has long eyed Turkey as one of its key emerging markets, but recent government action, which could see medicine access delayed by years, is giving it a wake-up call, ...
Market Insight - Power of observation propels comparative effectiveness research into the mainstream
02 March 2010
US agencies are making inroads in the use of comparative effectiveness research to support more robust decision-making. Observational studies are an emerging force in this area and promise to ...
 
Face to Face with Sandoz's "growth guy" Jeff George
04 March 2010
Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he ...
Interview: European Medicines Agency gets serious about its global strategy
29 January 2010
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth ...
Face to face: Ex-Novartis manager takes two-step approach to women's health at Lumavita
12 January 2010
Many pharmaceutical and biotech companies devote themselves to the discovery and development of novel drugs for unmet medical needs. However, with R&D costs and regulatory hurdles multiplying, and ...
 
Pfizer's fine: a revisit of self-regulation
10 September 2009
The US is a great place to do business. Being an almost free market, the profits are good, but so also are the temptations. So if you can't be bothered to put the money into a clinical trial to find a new indication for your product, you could ...
Commentary: 10 pro-innovation biopartnering trends
01 September 2009
1. risk aversion converges with focus on quality The rise and rise of the biotech sector and big pharma's increasing reliance on biological products as sources of future innovation are well established industry trends. Interesting, therefore, to ...
US agencies move forward with comparative effectiveness research plans
20 August 2009
As the US Congress debates the shape of a permanent comparative effectiveness research (CER) programme and who should run it, the agencies that received $1.1 billion in CER funding under an economic stimulus bill earlier this year have started ...
 
Decision models for assessing the cost effectiveness of drug-eluting stents
01 June 2005
Percutaneous coronary intervention is an increasingly common treatment for many people with coronary disease. Randomised trials using antiproliferative, drug-eluting stents (DES) have shown important reductions in the need for repeat procedures ...
 
COMPANY/ORGANISATION
CONDITION
GEOGRAPHY
DRUG
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Therapy Sector
Generics
Business
Policy & Regulation
Research & Development
International
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Scrip
Clinica
RAJ
Scrip Clinical Research
Animal Pharm